CVRx, Inc. — 2023 Form 10-K Summary
Business context and reporting period
CVRx is a commercial-stage medical-device company whose revenue is primarily from Barostim, an implantable neuromodulation device indicated in the U.S. to improve symptoms in certain patients with heart failure with reduced ejection fraction (HFrEF). This annual report covers the fiscal year ended December 31, 2023; comparisons are with 2022.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $39.3 million | $22.5 million |
| Gross profit / gross margin | $33.0 million / 84% | $17.5 million / 78% |
| Operating expenses | $76.1 million | $60.0 million |
| Operating loss | $(43.1) million | $(42.5) million |
| Net loss | $(41.2) million | $(41.4) million |
| Cash used in operating activities | $(39.0) million | $(42.7) million |
| Cash and cash equivalents at year-end | $90.6 million | $106.2 million |
U.S. revenue rose 95% to $35.1 million; Europe revenue declined 6% to $4.2 million. U.S. HFrEF revenue units increased to 1,123 from 587, and active implanting centers rose to 178 from 106. Higher gross margin reflected lower unit costs and higher average selling prices. SG&A grew 29% to $64.5 million, mainly from increased staffing, commercialization, marketing and travel.
At December 31, 2023, total assets were $115.2 million, current assets $112.1 million, current liabilities $7.9 million, total liabilities $39.3 million and stockholders’ equity $75.9 million. Long-term debt, net of unamortized costs and discounts, was $29.2 million; the company reported $30.0 million of term-loan principal outstanding. Accumulated deficit was $477.4 million. The filing reports no short-term investments separately from cash and cash equivalents.
Material changes and notable developments
- Revenue increased 75% year over year, driven by U.S. commercial expansion; European revenue and units declined.
- Gross margin improved six percentage points, while operating expenses increased 27%.
- In December 2023, the FDA approved expanded Barostim labeling incorporating longer-term BeAT-HF data and clarifying the indication.
- Effective January 1, 2024, Medicare outpatient reimbursement moved to New Technology APC 1580, with an average payment amount of $45,000. The prior temporary pass-through payment expired at the end of 2023.
- CVRx borrowed $22.5 million during 2023 under its Innovatus loan agreement. It also extended and expanded its Minneapolis facility lease.
- After year-end, CVRx announced Kevin Hykes as CEO effective February 12, 2024, succeeding Nadim Yared, who planned to retire.
Outlook, risks and unusual items
Management expects continued operating losses for at least several years while it invests in U.S. commercialization, sales capacity and product development. It believes existing cash resources, loan availability and revenue will fund forecasted operating liquidity, capital expenditures and debt service for at least three years; this assessment depends on assumptions and is not a guarantee. The filing gives no specific revenue or earnings guidance for 2024.
The loan bears a floating rate equal to the greater of prime or 5.50%, plus 2.65%, and matures in January 2028. Interest-only payments run through November 2027. An additional $20 million tranche may be available in 2024, subject to revenue and other conditions; a revenue performance covenant also applies under specified conditions. Debt is secured by substantially all personal property. CVRx reported compliance with loan covenants at year-end.
The BeAT-HF post-market phase met its primary safety endpoint but did not meet its primary effectiveness endpoint of cardiovascular mortality and heart-failure hospitalization. Other analyses favored Barostim, including sustained symptom measures, a Win Ratio of 1.26, and a directionally favorable 34% reduction in all-cause death, LVAD or transplant; these findings should not be treated as proof that the unmet primary endpoint was achieved.
Principal risks include continued losses and cash use; dependence on one product; physician, hospital and patient adoption; reimbursement and coverage; competition; reliance on limited-source suppliers and a single manufacturing site; regulatory and clinical requirements; and the need to sustain commercial growth. The company cites no material ongoing legal proceedings or accrued contingencies. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not audit internal control effectiveness.
Important facts for investors to verify
- Whether U.S. sales growth, implant-center expansion and physician adoption continue, and whether European sales stabilize.
- Actual hospital payment and procedure access under APC 1580, and whether commercial payors provide adequate coverage.
- Cash burn, cash runway and the assumptions behind management’s at-least-three-year liquidity estimate.
- Floating-rate debt costs, covenant compliance and eligibility for the additional loan tranche.
- Full context and statistical limitations of the post-market BeAT-HF results, particularly the unmet primary effectiveness endpoint.
- Progress and results of the BATwire clinical trial, as well as MDR review status for continued European commercialization.